Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial-Reference-Cited by-同舟云学术

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

Published:2008-05 Issue:5 Volume:7 Page:400-408
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Marks William J,Ostrem Jill L,Verhagen Leonard,Starr Philip A,Larson Paul S,Bakay Roy AE,Taylor Robin,Cahn-Weiner Deborah A,Stoessl A Jon,Olanow C Warren,Bartus Raymond T

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference30 articles.

1. Neuropathology of Parkinson's disease;Forno;J Neuropathol Exp Neurol,1996

2. The scientific basis for the current treatment of Parkinson's disease;Olanow;Ann Rev Med,2004

3. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease;Kordower;Science,2000

4. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease;Eslamboli;J Neurosci,2005

5. Functional recovery in parkinsonian monkeys treated with GDNF;Gash;Nature,1996

Cited by 489 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticle-based Gene Therapy for Neurodegenerative Disorders;Mini-Reviews in Medicinal Chemistry;2024-10

2. Gene therapy for polygenic or complex diseases;Biomarker Research;2024-09-04

3. Biomarkers of Parkinson's disease in perspective of early diagnosis and translation of neurotrophic therapies;Basic & Clinical Pharmacology & Toxicology;2024-07-08

4. Neurosurgical gene therapy for central nervous system diseases;Neurotherapeutics;2024-07

5. Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?;Neurotherapeutics;2024-07